RecruitingPhase 1NCT06841770

A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED)

Sponsor

Lineage Cell Therapeutics, Inc.

Enrollment

10 participants

Start Date

Jun 30, 2025

Study Type

INTERVENTIONAL

Conditions

Spinal Cord Injury Spinal Cord Injury Cervical Spinal Cord Injury, Chronic Spinal Cord Injury Thoracic Spinal Cord Injury, Acute

Summary

The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called OPC1 for people with spinal cord injury, spinal cord injury cervical, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.